Skip to main content
. 2021 Jan 4;8(4):2002228. doi: 10.1002/advs.202002228

Figure 7.

Figure 7

Schematic showing how ICAM‐1 activated by platelets increases endothelial permeability after insufficient RFA. ICAM‐1 in TAECs after insufficient RFA induces platelet aggregation and activation, increases endothelial permeability through Ezrin/VE‐cadherin, and facilitates tumor transendothelial migration. R300 is used for platelet deletion and anti‐ICAM‐1 antibody is used for blockade of ICAM‐1 for potential therapy.